Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer

Summary

The purpose of this phase Ib/II trial is to study the best dose and side effects of siltuximab and how well it works in combination with spartalizumab in treating patients with pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as siltuximab and spartalizumab, interfere with the ability of tumors cells to grow and spread.

General Information

NCT#: NCT04191421
Study ID: IRB00105616
Trial Phase: Phase I/II

Trial Sponsor: Novartis Pharmaceuticals, Emory University, EUSA Pharma
Therapies Used in This Trial: Spartalizumab, Siltuximab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search